Study to Evaluate the Immunogenicity and Safety of Heterologous SARS-CoV-2 Vaccine Schemes in an Elderly Population
NCT04983537 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120
Last updated 2021-07-30
Summary
To determine whether a heterologous vaccination regimen in individuals with no known previous history of COVID-19 is non-inferior to that observed with counterpart regimens currently in use in Argentina among a population of persons aged 66 or above.
Conditions
- COVID-19 Vaccines
Interventions
- DRUG
-
Gam-COVID-Vac / Gam-COVID-Vac
A comparison of antibody levels against protein S will be performed using the Gam-COVID-Vac / Gam-COVID-Vac group as a control group and the Gam-COVID-Vac / ChAdOx1 nCoV-19 and Gam-COVID-Vac / BBIBP-CorV groups as comparators.Comparisons will be made by contrasting the geometric means of antibody levels between each of the study arms. In addition, comparisons will be made as to whether or not the median antibody values of the alternative treatment groups are lower than: a) the 25th percentile of the median antibody value of the Gam COVID combination and b) whether the lower limit of the confidence interval of the differences in the GMC rate is lower than the conventional cut-off point of non-inferiority set at 0.67.
Sponsors & Collaborators
-
Ministerio de Salud de Ciudad Autónoma de Buenos Aires
lead OTHER_GOV
Study Design
- Allocation
- RANDOMIZED
- Purpose
- HEALTH_SERVICES_RESEARCH
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 66 Years
- Max Age
- 100 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2021-07-26
- Primary Completion
- 2021-09-26
- Completion
- 2021-09-26
Countries
- Argentina
Study Locations
More Related Trials
-
A Study to Assess the Safety and Immunogenicity of the Coronavac Vaccine Against COVID-19
NCT04756830 ·Status: UNKNOWN ·Phase: PHASE4
-
Humoral and Cellular Responses to Vaccination Against Coronavirus Disease 2019 (COVID-19) in the Very Elderly Living in Geriatric Institutions
NCT04961502 ·Status: UNKNOWN ·Phase: NA
-
A Study to Evaluate the Immunogenicity and Safety of A Recombinant Protein COVID-19 Vaccine as Booster Vaccines
NCT05933512 ·Status: UNKNOWN ·Phase: PHASE2
-
Homologous Booster Study of COVID-19 Protein Subunit Recombinant Vaccine
NCT05933278 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Immunogenicity Equivalence of a Homologous Third Dose of Covid-19 (Recombinante) Vaccine
NCT05142488 ·Status: UNKNOWN ·Phase: PHASE4
-
Immunogenicity and Safety of Heterologous and Homologous Boosting With ChAdOx1-S and CoronaVac or a Formulation of SCB-2019 (COVID-19)
NCT05087368 ·Status: UNKNOWN ·Phase: PHASE2
-
Effect of Different SARS-CoV-2 Vaccine Schedules and Vaccination Intervals on Reactogenicity and Humoral Immunogenicity
NCT05076227 ·Status: COMPLETED
-
ARVAC - A New Recombinant Coronavirus Disease 2019 (COVID-19) Vaccine
NCT05656508 ·Status: COMPLETED ·Phase: PHASE1
-
Safety of the Sputnik V Vaccine in Health Personnel of Private Effectors of the City of Buenos Aires, Argentina
NCT04738435 ·Status: COMPLETED
-
ARVAC-A New Recombinant Coronavirus Disease 2019 (COVID-19) Vaccine
NCT05752201 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Phase III of COVID-19 Vaccine EuCorVac-19 in Healthy Adults Aged 18 Years and Older
NCT05603052 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Learn About New COVID-19 RNA Vaccine Candidates in COVID-19 Vaccine-Experienced Healthy Individuals
NCT05472038 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Safety of UFRJvac, Trivalent COVID-19 Vaccine
NCT06303635 ·Status: NOT_YET_RECRUITING
-
A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults
NCT05703607 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Study to Evaluate Safety, Tolerability, & Immunogenicity of Multiple Formulations of BNT162b2 Against COVID-19 in Healthy Adults
NCT04816669 ·Status: COMPLETED ·Phase: PHASE3
-
Immunogenicity Study of the Covid-19 (Recombinante) Vaccine With a 4 or 8 Week Interval Between the First Doses.
NCT05157178 ·Status: UNKNOWN ·Phase: PHASE4
-
Evaluation of the Safety and Immunogenicity of SII Vaccine Constructs Based on the SARS-CoV-2 (COVID-19) Variant in Adults
NCT05029856 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age
NCT07300839 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Platform Trial to Compare Homologous Boost of Authorized COVID-19 Vaccines and Heterologous Boost With UB-612 Vaccine
NCT05293665 ·Status: UNKNOWN ·Phase: PHASE3
-
Immunogenicity After COVID-19 Vaccines in Adapted Schedules
NCT06189040 ·Status: COMPLETED ·Phase: PHASE4
-
Clinical Study of the Third Dose Immunization Schedule of COVID-19 Inactivated Vaccine, (Vero Cells) Based on Different COVID-19 Inactivated Vaccine in Adults Aged 18 Years and Above
NCT05163652 ·Status: UNKNOWN ·Phase: PHASE3
-
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SARS-CoV-2 Variant (BA.4 /5) mRNA Vaccine
NCT05636319 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Evaluation of Safety and Immunogenicity of a Novel Vaccine for Prevention of Covid-19 in Adults Previously Immunized
NCT05016934 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Immunogenicity,Safety and Cross - Immune Response With Mutant Strains of a Third Dose of an Inactivated COVID-19 Vaccine
NCT05329038 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
To Evaluate the Safety, and Immunogenicity of Vaccine Candidate Against COVID-19, in Healthy Adults
NCT04885361 ·Status: UNKNOWN ·Phase: PHASE1